Abstract
Cytosolic 5'-nucleotidase II (cN-II) is an intracellular 5'-nucleotidase characterized by substrate specificity. It preferentially hydrolyzes 6-hydroxypurine nucleotides such as IMP and GMP over AMP or UMP. cN-II is allosterically activated by ATP and inhibited by inorganic phosphate. It also has phosphotransferase activity and transfers phosphate moieties from IMP or GMP to nonphysiological nucleoside analogues used to treat some viral infections or malignancies. The cN-II gene has a strikingly conserved primary structure from humans to nematodes and its activity has been detected in various animals including snails. Its activity is highest in the livers of birds, crocodiles, lizards and snakes. The activity in chicken liver increases 2-fold by feeding a high-protein diet. These results suggest that cN-II participates, through IMP dephosphorylation, in production of uric acid as the main end product of aminonitrogen in these animals. Some studies suggest that cN-II participates in dephosphorylation of IMP accumulated in cells of some tissues to diffusible inosine for reutilization by other tissues. It has also been proposed that cN-II, together with purine nucleoside phosphorylase and hypoxanthine-guanine phosphoribosyltransferase, constitutes the “oxypurine cycle”, thus regulating intracellular phosphoribosyl pyrophosphate (PRPP) concentrations. As for intracellular dephosphorylation of AMP, another intracellular 5'-nucleotidase, cN-I, is supposed to participate, because it hydrolyzes AMP more preferentially than IMP or GMP. However, for the tissues, in which the expression of cN-I is very low or undetectable, e.g. liver or brain tissues, results have been obtained that suggest the participation of cN-II in intracellular dephosphorylation of AMP.
Keywords: Allosteric regulation, cN-II, Energy charge, Enzymatic properties, Physiological roles, 5'-Nucleotidase, Phosphotransferase.
Current Medicinal Chemistry
Title:Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Volume: 20 Issue: 34
Author(s): Roichi Itoh
Affiliation:
Keywords: Allosteric regulation, cN-II, Energy charge, Enzymatic properties, Physiological roles, 5'-Nucleotidase, Phosphotransferase.
Abstract: Cytosolic 5'-nucleotidase II (cN-II) is an intracellular 5'-nucleotidase characterized by substrate specificity. It preferentially hydrolyzes 6-hydroxypurine nucleotides such as IMP and GMP over AMP or UMP. cN-II is allosterically activated by ATP and inhibited by inorganic phosphate. It also has phosphotransferase activity and transfers phosphate moieties from IMP or GMP to nonphysiological nucleoside analogues used to treat some viral infections or malignancies. The cN-II gene has a strikingly conserved primary structure from humans to nematodes and its activity has been detected in various animals including snails. Its activity is highest in the livers of birds, crocodiles, lizards and snakes. The activity in chicken liver increases 2-fold by feeding a high-protein diet. These results suggest that cN-II participates, through IMP dephosphorylation, in production of uric acid as the main end product of aminonitrogen in these animals. Some studies suggest that cN-II participates in dephosphorylation of IMP accumulated in cells of some tissues to diffusible inosine for reutilization by other tissues. It has also been proposed that cN-II, together with purine nucleoside phosphorylase and hypoxanthine-guanine phosphoribosyltransferase, constitutes the “oxypurine cycle”, thus regulating intracellular phosphoribosyl pyrophosphate (PRPP) concentrations. As for intracellular dephosphorylation of AMP, another intracellular 5'-nucleotidase, cN-I, is supposed to participate, because it hydrolyzes AMP more preferentially than IMP or GMP. However, for the tissues, in which the expression of cN-I is very low or undetectable, e.g. liver or brain tissues, results have been obtained that suggest the participation of cN-II in intracellular dephosphorylation of AMP.
Export Options
About this article
Cite this article as:
Itoh Roichi, Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II., Current Medicinal Chemistry 2013; 20 (34) . https://dx.doi.org/10.2174/0929867311320340006
DOI https://dx.doi.org/10.2174/0929867311320340006 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Current Cancer Therapy Reviews Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design An Update on Extemporaneous Preparation of Radiopharmaceuticals Using Freeze-Dried Cold Kits
Mini-Reviews in Medicinal Chemistry The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Theranostic Applications of Nanomaterials in Alzheimer’s Disease: A Multifunctional Approach
Current Pharmaceutical Design The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors
Current Medicinal Chemistry Emerging Technologies for Fertility Preservation in Female Patients
Current Women`s Health Reviews New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery PAX6 expression may be protective against dopaminergic cell loss in Parkinson’s disease
CNS & Neurological Disorders - Drug Targets Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design